It is worth mentioning that the exact AA change in the borderland cohort was KRAS G12A, while the TARGET-ALL Phase II database included multiple AA changes in KRAS at position 12 (KRAS G12X). Here, KRAS is linked to acute lymphoblastic leukemia.